These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 16596213)

  • 1. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
    Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
    Platini C; Long J; Walter S
    Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
    [No Abstract]   [Full Text] [Related]  

  • 4. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
    Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
    Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
    Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
    Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
    Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
    Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
    Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
    Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
    Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of patients with meningeal carcinomatosis.
    Nakagawa H; Murasawa A; Kubo S; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
    J Neurooncol; 1992 May; 13(1):81-9. PubMed ID: 1613540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
    Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
    Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Shigekawa T; Takeuchi H; Misumi M; Matsuura K; Sano H; Fujiuchi N; Okubo K; Osaki A; Aogi K; Saeki T
    Breast Cancer; 2009; 16(1):88-92. PubMed ID: 18478315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.
    Zagouri F; Sergentanis TN; Bartsch R; Berghoff AS; Chrysikos D; de Azambuja E; Dimopoulos MA; Preusser M
    Breast Cancer Res Treat; 2013 May; 139(1):13-22. PubMed ID: 23588955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
    BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
    Figura NB; Long W; Yu M; Robinson TJ; Mokhtari S; Etame AB; Tran ND; Diaz R; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
    Breast Cancer Res Treat; 2018 Jun; 169(2):391-396. PubMed ID: 29392582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
    Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.